Literature DB >> 9443390

Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity.

E H Herman1, S E Lipshultz, N Rifai, J Zhang, T Papoian, Z X Yu, K Takeda, V J Ferrans.   

Abstract

The release of cardiac troponin T (cTnT) as a biomarker of doxorubicin-induced chronic cardiac injury was evaluated in the spontaneously hypertensive rat (SHR) model. Elevations in serum levels of cTnT and decreased immunohistochemical staining of heart sections for this protein were noted in SHRs treated with cumulative doses of doxorubicin (7 mg/kg) that induced only minimal histological alterations in myocytes. Concentrations of cTnT were further elevated, coincident with reduced immunohistochemical staining, in SHRs given 10-12 mg/kg doxorubicin. Thus, monitoring serum levels of cTnT can detect doxorubicin-induced myocyte damage in SHR and may prove useful for the noninvasive evaluation of this toxicity in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9443390

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  Cardiotoxicity of doxorubicin and other anthracycline derivatives.

Authors:  D Jain
Journal:  J Nucl Cardiol       Date:  2000 Jan-Feb       Impact factor: 5.952

2.  Molecular biology of doxorubicin-induced cardiomyopathy.

Authors:  J Umlauf; M Horký
Journal:  Exp Clin Cardiol       Date:  2002

Review 3.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

4.  Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.

Authors:  Li-Rong Yu; Zhijun Cao; Issam Makhoul; Jaclyn R Daniels; Suzanne Klimberg; Jeanne Y Wei; Jane Pf Bai; Jinong Li; Julia T Lathrop; Richard D Beger; Valentina K Todorova
Journal:  Exp Biol Med (Maywood)       Date:  2017-12-09

5.  Mechanisms and management of doxorubicin cardiotoxicity.

Authors:  Y Shi; M Moon; S Dawood; B McManus; P P Liu
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

Review 6.  Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.

Authors:  Eric S Christenson; Theodore James; Vineet Agrawal; Ben H Park
Journal:  Clin Biochem       Date:  2014-11-07       Impact factor: 3.281

7.  Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo.

Authors:  N P Dowd; M Scully; S R Adderley; A J Cunningham; D J Fitzgerald
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

8.  Phylogenetic origin of LI-cadherin revealed by protein and gene structure analysis.

Authors:  R Jung; M W Wendeler; M Danevad; H Himmelbauer; R Gessner
Journal:  Cell Mol Life Sci       Date:  2004-05       Impact factor: 9.261

9.  Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.

Authors:  Huan Meng; Wilson X Mai; Haiyuan Zhang; Min Xue; Tian Xia; Sijie Lin; Xiang Wang; Yang Zhao; Zhaoxia Ji; Jeffrey I Zink; Andre E Nel
Journal:  ACS Nano       Date:  2013-01-04       Impact factor: 15.881

10.  Cardiac biomarkers in HIV-exposed uninfected children.

Authors:  James D Wilkinson; Paige L Williams; Erin Leister; Bret Zeldow; William T Shearer; Steven D Colan; George K Siberry; Laurie B Dooley; Gwendolyn B Scott; Kenneth C Rich; Steven E Lipshultz
Journal:  AIDS       Date:  2013-04-24       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.